JP2005512522A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005512522A5 JP2005512522A5 JP2003538348A JP2003538348A JP2005512522A5 JP 2005512522 A5 JP2005512522 A5 JP 2005512522A5 JP 2003538348 A JP2003538348 A JP 2003538348A JP 2003538348 A JP2003538348 A JP 2003538348A JP 2005512522 A5 JP2005512522 A5 JP 2005512522A5
- Authority
- JP
- Japan
- Prior art keywords
- mut
- polypeptide
- nucleic acid
- drugs
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34371701P | 2001-10-26 | 2001-10-26 | |
| PCT/US2002/034381 WO2003035847A2 (en) | 2001-10-26 | 2002-10-25 | Il-13 mutein proteins, antibodies, compositions, methods and uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005512522A JP2005512522A (ja) | 2005-05-12 |
| JP2005512522A5 true JP2005512522A5 (https=) | 2006-01-05 |
Family
ID=23347323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003538348A Pending JP2005512522A (ja) | 2001-10-26 | 2002-10-25 | Ｉｌ−１３ムテインタンパク質、抗体、組成物、方法および使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20040023337A1 (https=) |
| EP (1) | EP1578912A4 (https=) |
| JP (1) | JP2005512522A (https=) |
| CA (1) | CA2464695A1 (https=) |
| WO (1) | WO2003035847A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040234499A1 (en) * | 2001-10-26 | 2004-11-25 | David Shealy | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
| ES2365210T3 (es) | 2002-06-14 | 2011-09-26 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health | Procedimientos de tratamiento y prevención de colitis en la que se implican la il-13 y los linfocitos t citolíticos naturales. |
| US20070104710A1 (en) * | 2002-06-28 | 2007-05-10 | Domants Limited | Ligand that has binding specificity for IL-4 and/or IL-13 |
| US20110223168A1 (en) * | 2002-12-27 | 2011-09-15 | Greg Winter | Ligand that has binding specificity for il-4 and/or il-13 |
| EP1444989A1 (en) * | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
| MXPA06000258A (es) * | 2003-07-15 | 2006-07-03 | Cambridge Antibody Tech | Moleculas de anticuerpo humano para interleucina-13. |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| PL3718564T3 (pl) | 2003-12-23 | 2024-03-18 | Genentech, Inc. | Nowe przeciwciała anty-IL 13 i ich zastosowania |
| US20050266005A1 (en) * | 2004-02-27 | 2005-12-01 | Heavner George A | Methods and compositions for treating IL-3 related pathologies |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US20070048785A1 (en) * | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| EP1824886B1 (en) | 2004-11-17 | 2010-12-22 | Amgen Inc. | Fully human monoclonal antibodies to il-13 |
| AU2006296399B2 (en) * | 2005-09-30 | 2011-01-20 | Medimmune Limited | Interleukin-13 antibody composition |
| WO2007045477A2 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Human antibodies against il-13 and therapeutic uses |
| WO2007147600A2 (en) * | 2006-06-21 | 2007-12-27 | Apogenix Gmbh | Differential il-4 and/or il-10 cytokine expression in human cancer |
| US20100086515A1 (en) * | 2006-07-06 | 2010-04-08 | Apogenix Gmbh | Human il-4 muteins in cancer therapy |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| EA201170357A1 (ru) * | 2008-08-20 | 2012-05-30 | Сентокор Орто Байотек Инк. | Инженерные антитела к il-13: композиции, способы и применение |
| WO2010121125A1 (en) | 2009-04-17 | 2010-10-21 | Wake Forest University Health Sciences | Il-13 receptor binding peptides |
| US20100291160A1 (en) * | 2009-05-13 | 2010-11-18 | Carver David R | Pharmaceutical system for trans-membrane delivery |
| RU2578468C2 (ru) | 2010-12-16 | 2016-03-27 | Дженентек, Инк. | Способы диагностики и лечения, связанные с ингибированием th2 |
| TWI719112B (zh) | 2011-03-16 | 2021-02-21 | 賽諾菲公司 | 雙重ｖ區類抗體蛋白質之用途 |
| TWI679019B (zh) | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物 |
| CN120904322A (zh) | 2013-09-13 | 2025-11-07 | 豪夫迈·罗氏有限公司 | 包含纯化的重组多肽的方法和组合物 |
| RU2016107435A (ru) | 2013-09-13 | 2017-10-18 | Дженентек, Инк. | Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты |
| CA2943326A1 (en) | 2014-04-11 | 2015-10-15 | Novartis Ag | Methods of selectively treating asthma using il-13 antagonists |
| TW201628647A (zh) | 2014-06-27 | 2016-08-16 | 賽諾菲公司 | 抗－ｉｌ４－ｉｌ１３雙特異性抗體 |
| CN110540590B (zh) | 2018-05-29 | 2023-08-18 | 康诺亚生物医药科技（成都）有限公司 | 一种自免疫抑制物的开发和应用 |
| JP7784898B2 (ja) | 2019-05-24 | 2025-12-12 | サノフイ | 全身性硬化症を治療するための方法 |
| US20220378877A1 (en) * | 2019-11-13 | 2022-12-01 | University Of Virginia Patent Foundation | Treatment of clostridium difficile infections |
| PE20231953A1 (es) | 2020-12-07 | 2023-12-06 | UCB Biopharma SRL | Anticuerpos multiespecificos y combinaciones de anticuerpos |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000044407A2 (en) * | 1999-02-01 | 2000-08-03 | Amgen Canada | Materials and methods to inhibit hodgkin and reed sternberg cell growth |
| WO2002100432A1 (en) * | 2001-06-08 | 2002-12-19 | Genaera Corporation | Methods for the modulation of il-13 |
| EP1206288B1 (en) * | 1999-08-02 | 2007-01-10 | The Regents Of The University Of Michigan | Targeted fiberless radiative effectors |
-
2002
- 2002-10-25 CA CA002464695A patent/CA2464695A1/en not_active Abandoned
- 2002-10-25 US US10/280,645 patent/US20040023337A1/en not_active Abandoned
- 2002-10-25 JP JP2003538348A patent/JP2005512522A/ja active Pending
- 2002-10-25 WO PCT/US2002/034381 patent/WO2003035847A2/en not_active Ceased
- 2002-10-25 EP EP02793830A patent/EP1578912A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005512522A5 (https=) | ||
| JP2007508011A5 (https=) | ||
| JP5918909B2 (ja) | 標的化治療薬 | |
| US20030049255A1 (en) | Interleukin-1 receptors in the treatment of diseases | |
| ES2680222T3 (es) | Modulación de los receptores con dominio Vps10p para el tratamiento de la enfermedad cardiovascular | |
| JP2003509378A (ja) | ＩＬ−１ｒａとＩＬ−１プロセシング・放出阻害化合物の併用療法 | |
| HRP20140982T1 (hr) | Ljudska anti-il-23 antitijela, pripravci, postupci i upotrebe | |
| CN103459595B (zh) | 针对人前列腺素e2受体ep4的抗体 | |
| KR20210132749A (ko) | 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ) | |
| JP2008525477A5 (https=) | ||
| TW200529853A (en) | Method of treatment of transplant rejection | |
| EP1575511A2 (en) | A new target for angiogenesis and anti-angiogenesis therapy | |
| JP2010534664A5 (https=) | ||
| ES2676406T3 (es) | Anticuerpos anti-Flt-1 en el tratamiento de la distrofia muscular de Duchenne | |
| CA2609349A1 (en) | Anti-mcp-1 antibodies, compositions, methods and uses | |
| KR20220044291A (ko) | 폴리펩티드 또는 그의 유도체의 적용 | |
| JP2011517548A5 (https=) | ||
| CN111417647A (zh) | 新型senolytic肽 | |
| ES2713068T3 (es) | Derivados de IGFBP-3 y usos de los mismos | |
| JP2022536289A (ja) | 抗炎症剤 | |
| TW202237634A (zh) | 用於治療ｃｏｖｉｄ－１９之ｄｓｇ２組成物和方法 | |
| EP4144364A1 (en) | Method and drug for treating spinal muscular atrophy | |
| KR20150070180A (ko) | 근위축성 측삭 경화증 치료제 | |
| US20090093415A1 (en) | Therapeutic agent for irritable bowel syndrome | |
| CN102741277A (zh) | 在治疗运动神经元疾病中的IFNγ抑制剂 |